Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference

Voting Period Ends December 5, 2014 at 5:00 p.m. ET.

NEW YORK, Dec. 3, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, is pleased to participate in the Buzz of BIO Contest in connection with the 2015 BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 17th Annual BIO CEO & Investor Conference features leading private and emerging public companies and will take place February 9-10, 2015 at the Waldorf Astoria in New York, NY. 

During the Buzz of BIO contest, individuals can vote for companies that have been nominated in each of two categories, "Most Distinguished Public Company" and "Most Promising Private Company." Winners will receive a complimentary company presentation and individual registration, plus promotion by BIO and BioCentury.

The voting period began at 9:00 a.m. ET on December 1, 2014 and ends at 5:00 p.m. ET on December 5, 2014.  The voting website is where individuals can select a company from the Most Distinguished Public Company and Most Promising Private Company categories.  Individuals are allowed to vote for one company per category per day.  Winners will then be contacted, and officially announced the following week.

"We are pleased to be nominated for the Buzz of BIO Contest in connection with this highly regarded investor conference," said Sergio Traversa, chief executive officer of Relmada Therapeutics.

About BIO CEO & Investor Conference

Now in its seventeenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.  The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.  The Company has a diversified portfolio of four lead products at various stages of development including LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; BuTab ER, its oral dosage form of the opioid analgesic buprenorphine; and MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine.  The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.  For more information, please visit Relmada's website at:

Forward-Looking Statements

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169

To view the original version on PR Newswire, visit:

SOURCE Relmada Therapeutics, Inc.